Compare GAIN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAIN | LXRX |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.3M | 660.9M |
| IPO Year | N/A | 2000 |
| Metric | GAIN | LXRX |
|---|---|---|
| Price | $15.38 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.75 | $4.15 |
| AVG Volume (30 Days) | 321.3K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 9.91% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | $4.38 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $13.14 | $0.49 |
| 52 Week High | $15.25 | $1.84 |
| Indicator | GAIN | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.71 | 64.34 |
| Support Level | $13.67 | $1.07 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 99.07 | 98.61 |
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.